Cardiac Marker Testing Devices Market 2026 : What Challenges and Opportunities?

Cardiac markers are diagnostic tool, which are associated for diagnosis and risk detection in patients suffering from chest pain, acute coronary syndrome (ACS), and acute myocardial infraction (MI). Cardiac marker test detects the endogenous substances, which are released during the blood circulation mainly when the heart is damaged or stressed, thereby, assessing risk and directing appropriate therapy that improves clinical outcome in high-risk patients. Cardiac markers are used in hospitals to either detect cardiac injury or to evaluate future risk of cardiovascular disease.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1039

Myoglobin, homocysteine, troponin T (cTnT), troponin I (cTnl), creatine kinase-MB (CK-MB), and C-reactive protein (CRP) are cardiac markers used for assessment of acute myocardial infraction. However, CK-MB, cTnl, and cTnT are used to identify and manage acute coronary syndrome in high-risk patients. Cardiac troponin I and T are most preferred and extensively used cardiac marker for myocardial injury, due to their higher sensitivity and specificity for diagnosis of myocardial infraction.

According to Journal of the American Medical Association (JAMA), in 2016, acute coronary syndrome is estimated as the major cause of morbidity and mortality worldwide. It is also responsible for over 1 million hospital admissions in the U.S. annually.  Increasing incidence of myocardial infraction (MI) or heart attack, acute coronary syndrome, and consistent development in cardiac markers by existing market players are some of the factors fueling growth of the cardiac marker testing devices market. Moreover, high blood pressure, high LDL cholesterol, smoking, unhealthy diet, diabetes, obesity, physical inactivity, and excessive alcohol consumption are some other factors which cause coronary heart disease and associated disorders. This in turn, is expected to drive growth of the global cardiac marker testing devices market in the near future.

Major acquisitions are expected to drive growth of the cardiac marker testing devices market

In 2017, U.S. Federal Trade Commission (FTC) allowed US$ 5.3 billion of acquisition of Alere’s point-of-care cardiac marker testing business to Abbott Laboratories. The deal between Abbott Laboratories and Alere created the world’s largest point-of-care testing business, which significantly strengthen and grow Abbott’s diagnostic presence in cardiac marker testing devices market.

Moreover, in 2017, FTC approved the deal of Alere’s Triage B-type Naturietic Peptide (BNP) assay business and Triage MeterPro toxicology and cardiovascular business with Quidel Corporation. The acquisition of Alere’s point-of-care cardiac marker testing business is expected to improve Quidel’s portfolio of rapid diagnostic testing solutions.

For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/cardiac-marker-testing-devices-market-1039

Key players in the cardiac marker testing devices market

Some of the key players operating in the global cardiac marker testing devices market are Bio-Rad Laboratories, Inc., Siemens Medical Solutions USA, Inc., Randox Laboratories Ltd., Abbott Laboratories, Becton, Dickinson and Company, Helomics Corp., LSI Medience Corporation, F.Hoffmann-La Roche Ltd., Enzo Biochem Inc., Ortho Clinical Diagnostics, Danaher Corporation, and bioMerieux SA.

Cardiac Marker Testing Devices Market Taxonomy:

By marker type:
• Lactate Dehydrogenase
• Creatine Kinase (CK)
◦ CK-MM
◦ CK-MB
◦ CK-BB
• Myoglobin
• Natriuretic Peptides
• Aspartate Aminotransferase (AST)
• Cardiac Troponin
• C-reactive Proteins
• Others (galectin-3, myeloperoxidase, homocysteine, H-FABP, and ischemia-modified albumin)

By product type:
• Instruments
◦ Chemiluminescence
◦ Immunofluorescence
◦ Immunochromatography
◦ ELISA
• Reagents and kits

By application:
• Acute Coronary Syndrome (ACS)
• Myocardial Infraction (MI)
• Cardiac Heart Failure
• Others

By testing type:
• Laboratory testing
• Pont-of-care testing

By end user:
• Hospitals
• Diagnostic Laboratory
• Home care setting

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1039

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.